Disease-Model & Isogenic iPSC Line Pairs
Matched mutant and corrected iPSC lines from the public banks, priced at both academic and commercial tiers.
| Category | Human & iPSC-Derived Cells |
|---|---|
| Unit | One cryopreserved vial or culture, per bank convention |
| Lead time | 2-6 weeks including MTA execution; longer where the pair spans two banks |
| Pricing | Published list price |
| Provenance | Partner manufactured |
| Data current | 2026-09-03 |
Description
An isogenic control is a line genetically identical to its comparator except at the edited locus, and it is the difference between a claim about a variant and a claim about two people. Two banks publish both fee tiers, which makes this the most price-legible corner of the iPSC market. Coriell's NIGMS Human Genetic Cell Repository charges $1,187.00 for US academic, non-profit and government purchasers and $1,878.00 for international, commercial or for-profit purchasers, a 1.58x multiplier, live-verified 2026-09-01 on line GM23338. RIKEN charges JPY 63,140 per tube for human iPS (HPS) lines on the not-for-profit tier and JPY 126,280 for-profit, an exact 2.00x, plus a separately itemised Clontech Laboratories licence fee of JPY 21,010 per cell line on the academic tier. EBiSC holds healthy controls, diagnosed disease lines and isogenic sub-clones across more than 45 diseases from donors aged 0 to 89, at GBP 1,442 per vial for BIONi015-A, under a single EBiSC Access and Use Agreement that covers lines from multiple distributors. The distribution fee is not the constraint. Coriell names the applicable limited use label licence on the line record itself, and for GM23338 that licence is held by iPS Academia Japan; BPS Bioscience states the same requirement on its own cardiomyocyte product page. RIKEN's definition of for-profit use is broader than most buyers expect and covers non-profit research aimed at patent acquisition. Commercial-tier pricing buys a tube on commercial terms; it does not grant rights to the underlying reprogramming patents, and the organisations that are careful about this price the two things separately.
Why this is hard to buy today
The distribution fee is published and small while the limited use label licence that decides whether a derivative can ever be commercialised is named in a remarks field on a catalogue record, priced by nobody, and follows the line into everything made from it.
Price evidence
Coriell NIGMS Human Genetic Cell Repository line GM23338: $1,187.00 US academic / non-profit / government and $1,878.00 international, commercial or for-profit, a 1.58x multiplier (live page fetch, 2026-09-01). Coriell NIA Repository, AG-prefix iPSC culture: $823.00 academic / $1,131.00 commercial (rate card, 2026-09-01). RIKEN BRC human iPS (HPS): JPY 63,140 per tube not-for-profit / JPY 126,280 for-profit, an exact 2.00x, plus a separately charged Clontech licence fee of JPY 21,010 per cell line on the academic tier (live fetch, 2026-09-01). EBiSC BIONi015-A: GBP 1,442 per vial; EBiSC-NEUR1 iPSC-derived neurons: GBP 1,160 per vial (live fetch, 2026-09-01). ATCC ACS-1013 hiPSC: $1,739.00 (live fetch, 2026-09-01). No bank publishes the cost of the third-party limited use label licence that several of them name on the line record.
These are supplier list prices we located and recorded, not a quotation from Wetware World. Your price depends on quantity, specification and freight, and is only binding once issued in writing.
What you must specify
A quote cannot be produced without these. Anything you leave open, a supplier will assume, usually expensively.
| # | Parameter |
|---|---|
| 01 | Named variant, zygosity, and whether the pair was made by correction or by introduction |
| 02 | Number of independent isogenic pairs required, since one pair controls for background but not for clonal idiosyncrasy |
| 03 | Allelic series requirement, including whether a knockout arm is needed to separate gain from loss of function |
| 04 | Sequencing evidence required for the edited locus in both members of the pair |
| 05 | Off-target analysis performed and its scope (in silico, exome, or whole genome) |
| 06 | Reprogramming method, because the patent landscape differs by route |
| 07 | Passage frozen and karyotype documentation |
| 08 | Intended use (research, commercial, patent-directed) for correct fee tier and MTA scoping |
| 09 | Named limited use label licences applicable to the line |
Quality documentation
Typically available with this item. What actually ships is confirmed on the quotation, per supplier.
- Certificate of analysis per bank
- Karyotype and pluripotency characterisation where the bank publishes it
- Genotype confirmation at the edited locus
- Donor consent and use-restriction documentation
Candidate suppliers
Organisations we have identified as capable. Listing does not imply a partnership, an endorsement, or that they have agreed to quote.
| Organisation | Basis for inclusion |
|---|---|
| Coriell Institute | NIGMS Human Genetic Cell Repository. Publishes both fee tiers, the full characterisation battery, passage frozen, karyotype, reprogramming method, and names the applicable limited use label licence on the line record. Line GM23338 fetched live 2026-09-01. |
| EBiSC (Fraunhofer) | Not-for-profit European bank holding healthy controls, diagnosed disease lines and isogenic sub-clones across more than 45 diseases, donors aged 0 to 89. A single EBiSC Access and Use Agreement covers lines from multiple distributors. States plainly that it cannot guarantee batch-specific delivery. Per-vial fees fetched live 2026-09-01. |
| RIKEN BioResource Research Center | National public bank publishing a full distribution fee schedule by resource class with an exact 2.00x for-profit multiplier, and charging the Clontech licence fee as a separate visible line item. Its definition of for-profit use includes non-profit research aimed at patent acquisition. Fetched live 2026-09-01. |
| ATCC | Public biorepository with catalogue prices published per line and per authentication service; provenance is the product. Prices re-fetched live 2026-09-01. |
Sources
doc WW-CL-16632 · rev 2026-09-03 · research use only · prices indicative and not binding until quoted in writing